SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Delaet Ingrid

(Last)

(First)

(Middle)

12780 EL CAMINO REAL

(Street)

SAN DIEGO

92130

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/09/2023

3. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Regulatory Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,382	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Incentive Stock Option	⁽¹⁾	02/01/2031	Common Stock	3,359	$106.02	D
Non-Qualified Stock Option	⁽¹⁾	02/01/2031	Common Stock	9,367	$106.02	D
Incentive Stock Option	⁽²⁾	01/31/2032	Common Stock	827	$79.02	D
Non-Qualified Stock Option	⁽²⁾	01/31/2032	Common Stock	12,261	$79.02	D
Restricted Stock Unit	⁽³⁾	⁽³⁾	Common Stock	4,717	⁽⁴⁾	D
Restricted Stock Unit	⁽⁵⁾	⁽⁵⁾	Common Stock	5,435	⁽⁴⁾	D
Restriced Stock Unit	⁽⁶⁾	⁽⁶⁾	Common Stock	3,202	⁽⁴⁾	D

Explanation of Responses:

1. Option granted February 1, 2021 and vests at 25% upon first anniversary (February 1, 2022) and remaining 75% vesting in 36 equal monthly installments beginning on March 1, 2022.

2. Option granted January 31, 2022 and vests monthly over four years.

3. 1/4 of the Restricted Stock Units vested on February 1, 2022 and February 1, 2023. The remaining units vest equally on each of February 1, 2024 and February 1, 2025.

4. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

5. 1/2 of the Restricted Stock Units vested on August 27, 2022. The remaining units will vest on August 27, 2023.

6. 1/4 of the Restricted Stock Units vested on January 31, 2023. The remaining units vest equally on each of January 31, 2024, January 31, 2025, January 26, 2026.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	02/15/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.